Oesophageal atresia and tracheo-oesophageal fistula Oesophageal atresia and tracheo-oesophageal fistula - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * English (US)EnglishPortuguês中文 * Log in * Personal account * Access through your institution(Open Athens) * Subscribe * Access through your institution * Log in * English (US)EnglishPortuguês中文 * HelpFAQsHow do I get access?Contact us When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance. OKCancelOesophageal atresia and tracheo-oesophageal fistula Menu Close * Overview * Theory * Diagnosis * Management * Follow up * Resources * Overview * Summary * Theory
Endoluminal gastroplication for gastro-oesophageal reflux disease Endoluminal gastroplication for gastro-oesophageal reflux disease Interventional procedures guidance Published: 1 March 2023 www.nice.org.uk/guidance/ipg753 Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare the introduction of new devices and procedures. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. This guidance replaces IPG404. 1 Recommendations 1.1 Evidence on the safety of endoluminal gastroplication for gastro-oesophageal reflux
Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease Interventional procedures guidance Published: 11 January 2023 www.nice.org.uk/guidance/ipg749 Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising of laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease (GORD) is adequate to support using this procedure provided that standard arrangements are in place for clinical governance, consent and audit. Find out what standard arrangements mean on the NICE interventional procedures guidance page. 1.2 Patient selection, and the procedure, should be done by clinicians who have specific
Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Pembrolizumab (Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2-positiv) – Nutzenbewertung gemäß § 35a SGB V. Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) Benefit assessment according to §35a SGB V1 EXTRACT Project: A24-01 Version: 1.0 Status: 26 Mar 2024 DOI: 10.60584/A24-01_en Extract of dossier assessment
Nivolumab (Opdivo) - for patients with metastatic or locally advanced and unresectable, deficient mismatch repair (dMMR) / high microsatellite instability (MSI?H) oesophageal and gastric cancer Prepared by the All Wales Therapeutics and Toxicology Centre Page 1 of 5 One Wales Medicines Assessment Group Recommendation: Nivolumab monotherapy as a first-line treatment for patients with metastatic or locally advanced and unresectable, deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) oesophageal and gastric cancer (OW28) ONE WALES INTERIM DECISION Nivolumab monotherapy as a first-line treatment for patients with metastatic or locally advanced and unresectable, deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) oesophageal and gastric cancer. Date
the last dose of the study medication. This alone is unsuitable to represent health-related quality of life (see Section 2.4.1). ECS: oesophageal cancer subscale; FACT-E: Functional Assessment of Cancer Therapy-Esophageal; RCT: randomized controlled trial; VAS: visual analogue scale Health status was not observed over the entire study period, but over a relevant period of up to 2 years after completion Nivolumab (oesophageal or gastro-oesophageal junction cancer) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Nivolumab (Karzinome des Ösophagus oder gastroösophagealen Übergangs, adjuvant) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 November 2021). Please